KKRC
TLSI icon

Kohlberg Kravis Roberts & Co’s TriSalus Life Sciences TLSI Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,601
Closed -$195K – 212
2021
Q3 		$195K Buy
+19,601
New +$192K ﹤0.01% 158

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's TLSI Position: Q4 2021 in Review

Kohlberg Kravis Roberts & Co sold out of TriSalus Life Sciences (TLSI) in Q4 2021, closing a stake of 19,601 shares — an estimated $195K sold.

Kohlberg Kravis Roberts & Co first reported a position in TLSI in Q3 2021 and held it in 1 quarter. The position peaked at $195K in Q3 2021. 68 funds tracked by Wall St. Rank hold TLSI as of Q4 2021.

  • Kohlberg Kravis Roberts & Co reported no remaining TriSalus Life Sciences position as of Q4 2021 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 19,601 TriSalus Life Sciences shares in Q4 2021, an estimated $195K.
  • Kohlberg Kravis Roberts & Co first reported a position in TriSalus Life Sciences in Q3 2021 and held it in 1 quarter.
  • Kohlberg Kravis Roberts & Co's TriSalus Life Sciences position peaked at $195K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2021.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q4 2021, filed 14 Feb 2022.